There are 360 resources available
155P - BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT
Presenter: Konrad Klinghammer
Session: Poster Display
41P - Single-Cell Signalling Analysis of Engineered γδ T cell Biotherapeutics for the Treatment of Colorectal Cancer
Presenter: Callum Nattress
Session: Poster Display
42P - Tumor-reactive CD8+ T cells in ovarian and colon cancer in tumors and cell products
Presenter: Sara Bobisse
Session: Poster Display
157P - Phase 1 expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma
Presenter: Randy Sweis
Session: Poster Display
158P - Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA.
Presenter: John Moroney
Session: Poster Display
44P - In situ CAR Therapy Using oRNA™ Lipid Nanoparticles Regresses Tumors in Mice
Presenter: Robert Mabry
Session: Poster Display
159P - COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant epithelial ovarian cancer.
Presenter: Oladapo Yeku
Session: Poster Display
45P - The RevCAR T cell platform: a switchable and combinatorial therapeutic strategy for glioblastoma
Presenter: Nicola Mitwasi
Session: Poster Display